Tumor LAG-3 and NY-ESO-1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer.

摘要: Background Immune checkpoint inhibitors (ICIs) are an established treatment for non-small cell lung cancer (NSCLC) that have demonstrated durable clinical benefits (DCBs). Previous studies suggested NY-ESO-1 and LAG-3 to be surrogate markers of ICI responses in NSCLC; therefore, we explored the predictive value their expression NSCLC. Methods We retrospectively reviewed records 38 patients with advanced NSCLC treated anti-PD-1 monoclonal antibodies from 2013 2016 at Seoul National University Hospital Bundang after failed platinum-based chemotherapy. Tumor tissues each patient were subjected immunohistochemical analysis determine NY-ESO-1, LAG-3, PD-L1 expression, whose ability predict progression-free survival (PFS) overall (OS) was then analyzed alongside positive (PPV) negative (NPV) values. Results or detected all tumor samples high significantly associated favorable outcomes, unlike expression. Patients both NY-ESO-1- LAG-3-expressing tumors had a DCB rate those triple-positive PD-L1, NY-ESO superior median OS PFS than triple-negative Furthermore, co-expression independent predictor OS, while displayed good NPV. Conclusions who co-express exhibit greater DCBs improved long-term following therapy. Moreover, could novel biomarkers should considered future use ICIs.